



October 15th, 2025

Company Name: GENOVA Inc.
 Representative: President and Representative Director,
 Tomoki Hirase
 (Ticker: 9341: Tokyo Stock Exchange Prime Market)
 Inquiries: Board Director and Executive Officer,
 Akinao Ueda

Notice Regarding Differences Between the Forecast and Actual Results for the Second Quarter (Cumulative) and Revisions to the Full-Year Business Forecast (Consolidated) and the Reduction of Performance-based Compensation

We would like to inform you that, considering recent business performance trends, we have revised its full-year business forecast for FY3/2026, which was previously revised on August 8th, 2025, as outlined below. In addition, to clarify management responsibility regarding the downward revision of the business forecast, we will implement a reduction in executive compensation.

1. Revision of the Consolidated Forecast for the First Half of the Fiscal Year Ending March 31, 2026 (April 1, 2025 – September 30, 2025)

	Net sales	Operating profit	Recurring profit	Net Profit attributable to owners of the parent	Earnings per share
Previous Forecast (A)	Million yen 6.066	Million yen 387	Million yen 386	Million yen 253	14.66 yen
Revised Forecast (B)	5.023	78	86	160	9.28 yen
Increase/Decrease (B-A)	△1.043	△309	△300	△93	
Change Rate (%)	△17.1%	△79.8%	△77.7%	△36.8%	
(Reference) Results for the Previous Fiscal Year (FY3/2025)	5.143	1.217	1.203	814	45.79 yen

2. Revision of the Consolidated Forecast for the Full Fiscal Year (April 1, 2025 – March 31, 2026)

	Net sales	Operating profit	Recurring profit	Net Profit attributable to owners of the parent	Earnings per share
Previous Forecast (A)	Million yen 14.013	Million yen 1.361	Million yen 1.359	Million yen 904	52.25 yen
Revised Forecast (B)	11.332	477	482	417	24.11 yen
Increase/Decrease (B-A)	△2.681	△884	△877	△487	
Change Rate (%)	△23.7%	△65.0%	△64.5%	△53.9%	
(Reference) Results for the Previous Fiscal Year (FY3/2025)	10.006	2.026	2.018	1.413	79.78 yen

2. Reasons for the Revision

In the first quarter of the fiscal year ending March 2026, growth continued to slow due to sluggish pageviews in the medical platform business. This has become transparent since the second half of last fiscal year due to the changes in the competitive environment caused by generative AI, including ChatGPT, resulting in lower revenue and profits in the first quarter compared to the same period last fiscal year. Although monthly progress was on a recovery trend in the second quarter, the deviation from the earnings forecasts disclosed became clearer, leading to the revision of the earnings forecasts for the first half of the year. In addition, as a fundamental solution to the business environment has not yet been clarified, the full-year earnings forecast will be revised to reflect the trends in the first half of the year.

Our top priority will be to rebuild our core medical platform business. At the same time, we will work to restore our smart clinic business, which has seen slower progress in terms of human resources since last fiscal year, by increasing staff numbers and strengthening our training system. In addition, we will simultaneously develop new businesses and services, strengthen our platform, and provide new DX solutions, in order to secure further sales from both new and existing customers. There will be no revisions to the earnings forecasts of our subsidiary, ASANO Co., Ltd.

There will be no change to the dividend forecast as a result of this revision of the earnings forecast.

3. Reduction of Executive Compensation

The Board of Directors has resolved to reduce executive compensation as outlined below, in recognition of the downward revision of the business forecast described in Section 1 and to clarify management accountability.

(1) Details of the Reduction

President and Representative Director 30% reduction in monthly compensation

(2) Period of Reduction

From October 2025 to March 2026 (6 months)